Inverse genetic associations exist between serum 25-hydroxyvitamin D (S-25[OH]D) and nonalcoholic fatty liver disease (NAFLD), as deciphered from a bidirectional mendelian randomization trial published in "Clinical Gastroenterology and Hepatology". Researchers sought to identify the connection between S-25(OH)D and NAFLD.

At the genome-wide-significance level, 7 and 6 independent genetic variants linked with S-25(OH)D and NAFLD, respectively, were chosen as the variables. For S-25(OH)D, the study of underlying genetic determinants of vitamin D and highly linked traits consortium, which incorporated 79366 people, provided summary-level data.

The UK Biobank study (360919 controls and 275 cases), the FinnGen consortium (217,898 controls and 894 cases), and a genome-wide correlation meta-analysis (17,781 controls and 1483 cases), all provided summary-level data for NAFLD. Four liver enzymes' summary-level data were gathered from the UK Biobank.

There were genetic links of S-25(OH)D with NAFLD and specific liver enzymes. Higher S-25(OH)D levels that were genetically predicted were found to be consistently linked with a lower chance of developing NAFLD in the three sources. The combined odds ratio of NAFLD was 0.78 for a 1-SD rise in genetically anticipated S-25(OH)D levels.

S-25(OH)D levels that were genetically predicted to be higher exhibited a borderline correlation with aspartate aminotransferase levels (change -1.17). S-25(OH)D was not linked to NAFLD genetic predisposition (change 0.13). Thus, S-25(OH)D appears to be inversely linked with NAFLD.